Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UR6PS000391 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Centers for Disease Control and Prevention | FED |
| National Institute on Drug Abuse (NIDA) | NIH |
| AIDS Project Hartford | INDUSTRY |
| Connecticut State, Department of Correction |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Project PLUS tests an HIV risk reduction/adherence behavioral intervention with HIV-infected individuals in Connecticut prisons. Participants are randomly assigned to one of three groups: prior to release from incarceration (Group 1), after release from incarceration (Group 2), and treatment-as-usual (Group 3). We hypothesize that the intervention groups (Groups 1 & 2) will demonstrate significantly greater knowledge regarding drug- and sex- related HIV risk behavior and HIV medication adherence, greater motivation to reduce HIV risk behavior and improve HIV medication adherence, and enhanced skills for engaging in HIV risk reduction behavior and HIV medication adherence vs. the treatment-as-usual group. We will also compare these outcomes between Groups 1 and 2.
Project PLUS is an HIV risk reduction/Highly Active Antiretroviral Therapy (HAART) adherence behavioral intervention for persons being released from prisons in Connecticut. The intervention is delivered one-on-one to HIV-infected individuals prior to release from incarceration (Group 1) vs. after release from incarceration (Group 2) vs. treatment as usual (Group 3). The primary hypothesis is that the intervention groups (Groups 1 & 2) will demonstrate significantly greater reduction in rates of HIV sexual and drug risk behaviors and a significantly greater increase in HAART adherence compared to Group 3 participants at 4 months following release from prison. (However, those in Group 3 may come back to participate in the educational sessions, as non-study participants, after their participation has been completed). Based on the IMB model of health behavior change, the primary outcomes of interest are HIV risk reduction knowledge, motivation, behavioral skills (Fisher & Fisher, 1992) and specific event-level partner-by-partner drug and sex risk outcomes including the frequency of unprotected sex episodes across different partners categorized by perceived HIV-status of each partner, numbers of different sexual partners, changes in the frequency of condom use, changes in reported adherence to HIV medication, and changes in reported drug use episodes across different partners categorized by perceived HIV-status of each partner. Additional outcomes of interest include greater knowledge regarding drug- and sex- related HIV risk behaviors and HAART adherence, greater motivation to reduce HIV risk behaviors and improve HAART adherence, enhanced skills for engaging in HIV risk reduction behaviors and HAART adherence. A comparison between Groups 1 & 2 has never been examined, so an important part of this study is to explore this comparison.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pre-release | Experimental | Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release. |
|
| Post-release | Experimental | Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release. |
|
| Control | No Intervention | Participants in the control group do not receive education sessions during their term in the study. However, these sessions are available to them after completing the study. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pre-Release (Group 1) | Behavioral | Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release. |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of unprotected sex episodes across different partners categorized by perceived HIV-status of each partner | Pre-release, Day of Release, 1-mo ff-up, 3-mo ff-up | |
| Numbers of different sexual partners | Pre-release, Day of Release, 1-mo ff-up, 3-mo ff-up | |
| Changes in the frequency of condom use reported | Pre-release, Day of Release, 1-mo ff-up, 3-mo ff-up | |
| Changes in reported HIV medication adherence | Pre-release, Day of Release, 1-mo ff-up, 3-mo ff-up | |
| Changes in reported drug use episodes across different partners categorized by perceived HIV-status of each partner | Pre-release, Day of Release, 1-mo ff-up, 3-mo ff-up |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frederick Altice, MD | Yale University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Yale AIDS Program, Yale University School of Medicine | New Haven | Connecticut | 06510 | United States |
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| D040242 | Risk Reduction Behavior |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
| UNKNOWN |
Not provided
Not provided
Not provided
Not provided
Not provided
| Post-release (Group 2) | Behavioral | Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release. |
|
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
| D001519 | Behavior |